- Active not recruitingPHASE3
A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
This study is testing a new medicine, remibrutinib, for adults with a type of chronic (long-lasting) hives that hasn't improved with usual antihistamine tablets. It will check if the medicine works, is safe, and is well-tolerated. Some people will receive a dummy treatment (placebo) at first.
For: Chronic Inducible UrticariaUnited States · Argentina · Australia - Active not recruitingPHASE3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
This study is comparing a new medication called remibrutinib with an existing treatment, teriflunomide, for people with relapsing multiple sclerosis (RMS). It aims to see how well remibrutinib works and if it's safe to use in managing RMS symptoms.
For: Relapsing Multiple SclerosisUnited States · Argentina · Austria - Active not recruitingPHASE3
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
This study is looking at a new medicine called remibrutinib for people with relapsing multiple sclerosis (RMS). It compares remibrutinib to an existing medicine, teriflunomide, to see how well it works and if it's safe. It's a large study, involving about 800 people.
For: Relapsing Multiple SclerosisUnited States · Argentina · Brazil - RecruitingPHASE2
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria
This study is testing a new medicine, remibrutinib, for chronic urticaria, also known as chronic hives. We want to see how well it works and how safe it is for people whose hives haven't improved with other treatments.
For: Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU)United States · France · Germany - RecruitingPHASE3
Remibrutinib Open Label Roll-over Post-trial Access Protocol
This study is for people already taking remibrutinib in a Novartis trial who are benefiting from it. It allows them to keep taking the medicine to see its long-term effects, especially if they can't get it otherwise.
For: Indication of the Parent ProtocolCanada · South Korea - Active not recruitingPHASE3
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
This study looks at a new medicine called remibrutinib for chronic spontaneous urticaria (CSU), comparing it to a dummy treatment (placebo) and another existing medicine, omalizumab. It aims to see if remibrutinib is safe and helps reduce hives and itching in adults whose CSU isn't well controlled by usual allergy medicines.
For: Chronic Spontaneous UrticariaArgentina · Brazil · Bulgaria